Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies

Maiko Matsushita, Rie Yamazaki, Hideyuki Ikeda, Yutaka Kawakami

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

PRAME (Preferentially expressed antigen of melanoma), highly expressed in various solid tumor cells and normal testis, was first isolated as a human melanoma antigen recognized by cytotoxic T cells (CTL). This gene was also expressed in some of the hematological malignancies, including acute myelogenous leukemia (AML) and multiple myeloma. We and others have extensively evaluated the PRAME expression in various hematological malignancies and demonstrated high expression of the PRAME gene in subsets of AML, chronic myelogenous leukemia, acute lymphocytic leukemia, lymphoma and multiple myeloma. In addition, we have demonstrated that PRAME was a useful marker for detection of minimal residual disease (MRD) in patients with leukemia, particularly those leukemias in which tumor specific markers are currently unavailable. Since PRAME was first identified as a tumor antigen recognized by T cells, the possibility that PRAME is a leukemia antigen recognized by T cells was evaluated, and it was found that PRAME-positive leukemia cell lines and fresh leukemia cells were susceptible to lysis by the PRAME-specific CTL. Five CTL epitopes associated with either HLA-A*0201 or HLA-A*2402 have recently been identified. It is, therefore, an attractive strategy to apply PRAME specific immunotherapy on patients with PRAME positive leukemia in MRD condition.

Original languageEnglish
Pages (from-to)439-444
Number of pages6
JournalLeukemia and Lymphoma
Volume44
Issue number3
DOIs
Publication statusPublished - 2003 Mar 1

Fingerprint

Melanoma-Specific Antigens
Hematologic Neoplasms
Leukemia
Therapeutics
Residual Neoplasm
Multiple Myeloma
T-Lymphocytes
Acute Myeloid Leukemia
T-Lymphocyte Epitopes
HLA-A Antigens
Neoplasm Antigens
B-Cell Chronic Lymphocytic Leukemia
Tumor Biomarkers
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunotherapy
Genes
Testis

Keywords

  • Acute myelogenous leukemia
  • Hematological malignancies
  • Immunotherapy
  • Preferentially expressed antigen of melanoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. / Matsushita, Maiko; Yamazaki, Rie; Ikeda, Hideyuki; Kawakami, Yutaka.

In: Leukemia and Lymphoma, Vol. 44, No. 3, 01.03.2003, p. 439-444.

Research output: Contribution to journalArticle

@article{bd78b61a3b8643c9a1a91982f1ca7f89,
title = "Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies",
abstract = "PRAME (Preferentially expressed antigen of melanoma), highly expressed in various solid tumor cells and normal testis, was first isolated as a human melanoma antigen recognized by cytotoxic T cells (CTL). This gene was also expressed in some of the hematological malignancies, including acute myelogenous leukemia (AML) and multiple myeloma. We and others have extensively evaluated the PRAME expression in various hematological malignancies and demonstrated high expression of the PRAME gene in subsets of AML, chronic myelogenous leukemia, acute lymphocytic leukemia, lymphoma and multiple myeloma. In addition, we have demonstrated that PRAME was a useful marker for detection of minimal residual disease (MRD) in patients with leukemia, particularly those leukemias in which tumor specific markers are currently unavailable. Since PRAME was first identified as a tumor antigen recognized by T cells, the possibility that PRAME is a leukemia antigen recognized by T cells was evaluated, and it was found that PRAME-positive leukemia cell lines and fresh leukemia cells were susceptible to lysis by the PRAME-specific CTL. Five CTL epitopes associated with either HLA-A*0201 or HLA-A*2402 have recently been identified. It is, therefore, an attractive strategy to apply PRAME specific immunotherapy on patients with PRAME positive leukemia in MRD condition.",
keywords = "Acute myelogenous leukemia, Hematological malignancies, Immunotherapy, Preferentially expressed antigen of melanoma",
author = "Maiko Matsushita and Rie Yamazaki and Hideyuki Ikeda and Yutaka Kawakami",
year = "2003",
month = "3",
day = "1",
doi = "10.1080/1042819021000035725",
language = "English",
volume = "44",
pages = "439--444",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies

AU - Matsushita, Maiko

AU - Yamazaki, Rie

AU - Ikeda, Hideyuki

AU - Kawakami, Yutaka

PY - 2003/3/1

Y1 - 2003/3/1

N2 - PRAME (Preferentially expressed antigen of melanoma), highly expressed in various solid tumor cells and normal testis, was first isolated as a human melanoma antigen recognized by cytotoxic T cells (CTL). This gene was also expressed in some of the hematological malignancies, including acute myelogenous leukemia (AML) and multiple myeloma. We and others have extensively evaluated the PRAME expression in various hematological malignancies and demonstrated high expression of the PRAME gene in subsets of AML, chronic myelogenous leukemia, acute lymphocytic leukemia, lymphoma and multiple myeloma. In addition, we have demonstrated that PRAME was a useful marker for detection of minimal residual disease (MRD) in patients with leukemia, particularly those leukemias in which tumor specific markers are currently unavailable. Since PRAME was first identified as a tumor antigen recognized by T cells, the possibility that PRAME is a leukemia antigen recognized by T cells was evaluated, and it was found that PRAME-positive leukemia cell lines and fresh leukemia cells were susceptible to lysis by the PRAME-specific CTL. Five CTL epitopes associated with either HLA-A*0201 or HLA-A*2402 have recently been identified. It is, therefore, an attractive strategy to apply PRAME specific immunotherapy on patients with PRAME positive leukemia in MRD condition.

AB - PRAME (Preferentially expressed antigen of melanoma), highly expressed in various solid tumor cells and normal testis, was first isolated as a human melanoma antigen recognized by cytotoxic T cells (CTL). This gene was also expressed in some of the hematological malignancies, including acute myelogenous leukemia (AML) and multiple myeloma. We and others have extensively evaluated the PRAME expression in various hematological malignancies and demonstrated high expression of the PRAME gene in subsets of AML, chronic myelogenous leukemia, acute lymphocytic leukemia, lymphoma and multiple myeloma. In addition, we have demonstrated that PRAME was a useful marker for detection of minimal residual disease (MRD) in patients with leukemia, particularly those leukemias in which tumor specific markers are currently unavailable. Since PRAME was first identified as a tumor antigen recognized by T cells, the possibility that PRAME is a leukemia antigen recognized by T cells was evaluated, and it was found that PRAME-positive leukemia cell lines and fresh leukemia cells were susceptible to lysis by the PRAME-specific CTL. Five CTL epitopes associated with either HLA-A*0201 or HLA-A*2402 have recently been identified. It is, therefore, an attractive strategy to apply PRAME specific immunotherapy on patients with PRAME positive leukemia in MRD condition.

KW - Acute myelogenous leukemia

KW - Hematological malignancies

KW - Immunotherapy

KW - Preferentially expressed antigen of melanoma

UR - http://www.scopus.com/inward/record.url?scp=0037344936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037344936&partnerID=8YFLogxK

U2 - 10.1080/1042819021000035725

DO - 10.1080/1042819021000035725

M3 - Article

C2 - 12688312

AN - SCOPUS:0037344936

VL - 44

SP - 439

EP - 444

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -